109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
细胞角蛋白 19 表达对不可切除肝细胞癌靶向治疗和免疫治疗结局的影响：倾向评分匹配分析
Authors Liu J, Yuan T, Lv X, Tan G, Xue L, Huang Z
Received 21 July 2025
Accepted for publication 30 September 2025
Published 10 October 2025 Volume 2025:12 Pages 2295—2305
DOI https://doi.org/10.2147/JHC.S555248
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr David Gerber
Junjie Liu,1,2 Tong Yuan,1,2 Xing Lv,1,2 Guan Tan,1,2 Lin Xue,1,2 Zhiyong Huang1,2
1Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 2Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
Correspondence: Zhiyong Huang, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China, Email huangzy@tjh.tjmu.edu.cn
Background: Cytokeratin 19 (CK19) serves as a significant prognostic indicator for hepatocellular carcinoma (HCC). However, it is uncertain if CK19 expression influences the prognosis and effectiveness of treatment in patients undergoing targeted therapy and immunotherapy for unresectable HCC. This study aimed to evaluate the prognostic value of CK19 expression in this patient population.
Methods: Patients with unresectable HCC who received combined targeted therapy and immunotherapy between January 2021 and December 2023 were retrospectively analyzed in this study. CK19 expression in tumor biopsy samples from patients before treatments were identified using immunohistochemistry. Propensity score matching (PSM) was conducted in a 1:2 ratio to balance baseline features between the CK19-positive and CK19-negative groups. Survival outcomes were analyzed using the Kaplan-Meier method along with the Cox regression model. Treatment response was evaluated based on mRECIST criteria.
Results: A total of 247 patients were included, and 126 were selected after-PSM (43 CK19-positive, 83 CK19-negative), with balanced baseline characteristics. After PSM, the CK19-negative group had a markedly prolonged median OS compared to the CK19-positive group (42.2 months vs 15.6 months, p < 0.001), along with an extended median PFS (28.9 months vs 7.3 months, p < 0.001). The ORR was significantly higher in the CK19-negative group than in the CK19-positive group (59.0% vs 18.6%, p < 0.001), and the DCR was also superior (96.4% vs 79.1%, p = 0.005). Multivariate Cox analysis found CK19 expression as an independent factor predicting OS and PFS.
Conclusion: In patients with unresectable HCC undergoing targeted therapy and immunotherapy, CK19 expression correlated with poorer survival outcomes and diminished therapeutic response. CK19 may serve as a valuable biomarker for prognosis and treatment stratification in advanced HCC, and CK19 screening may be incorporated into clinical trial stratification and clinical decision-making.
Keywords: hepatocellular carcinoma, cytokeratin 19, immunotherapy, targeted therapy, prognosis, propensity score matching
1Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China; 2Hubei Key Laboratory of Hepato-Pancreato-Biliary Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
Correspondence: Zhiyong Huang, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China, Email huangzy@tjh.tjmu.edu.cn
Background: Cytokeratin 19 (CK19) serves as a significant prognostic indicator for hepatocellular carcinoma (HCC). However, it is uncertain if CK19 expression influences the prognosis and effectiveness of treatment in patients undergoing targeted therapy and immunotherapy for unresectable HCC. This study aimed to evaluate the prognostic value of CK19 expression in this patient population.
Methods: Patients with unresectable HCC who received combined targeted therapy and immunotherapy between January 2021 and December 2023 were retrospectively analyzed in this study. CK19 expression in tumor biopsy samples from patients before treatments were identified using immunohistochemistry. Propensity score matching (PSM) was conducted in a 1:2 ratio to balance baseline features between the CK19-positive and CK19-negative groups. Survival outcomes were analyzed using the Kaplan-Meier method along with the Cox regression model. Treatment response was evaluated based on mRECIST criteria.
Results: A total of 247 patients were included, and 126 were selected after-PSM (43 CK19-positive, 83 CK19-negative), with balanced baseline characteristics. After PSM, the CK19-negative group had a markedly prolonged median OS compared to the CK19-positive group (42.2 months vs 15.6 months, p < 0.001), along with an extended median PFS (28.9 months vs 7.3 months, p < 0.001). The ORR was significantly higher in the CK19-negative group than in the CK19-positive group (59.0% vs 18.6%, p < 0.001), and the DCR was also superior (96.4% vs 79.1%, p = 0.005). Multivariate Cox analysis found CK19 expression as an independent factor predicting OS and PFS.
Conclusion: In patients with unresectable HCC undergoing targeted therapy and immunotherapy, CK19 expression correlated with poorer survival outcomes and diminished therapeutic response. CK19 may serve as a valuable biomarker for prognosis and treatment stratification in advanced HCC, and CK19 screening may be incorporated into clinical trial stratification and clinical decision-making.
Keywords: hepatocellular carcinoma, cytokeratin 19, immunotherapy, targeted therapy, prognosis, propensity score matching